An in vivo efficacy validation and immune-modulatory potential of Streptomyces sp (original) (raw)
Related papers
Immune Response to Streptomyces lividans in Mice: A Potential Vaccine Vehicle Against TB
The Open Vaccine Journal, 2009
The potentialities of Streptomyces lividans 1326 as new live vaccine vehicle strategy have been evaluated. Immunization of mice with the Streptomyces mycelium induced high levels of specific antibodies against proteins released in the culture supernatant of the analyzed strain. Splenocytes from the Streptomyces-immunized animals were able to secrete high levels of IFN-(2103.9 pg/mL) and to proliferate in vitro on stimulation with proteins released by Streptomyces. The analysis of cross-reactivity against M. tuberculosis secreted proteins showed that the immunization of mice with Streptomyces led to a comparable level of cross-reacting antibodies as in the BCG immunized mice. Similarly sera antibodies from Streptomyces immunized group recognized whole BCG cells to the same degree as antibodies raised against BCG reacted with Streptomyces mycelium, indicating that these two actinobacteria cross-react immunologically.
Evaluating the Antibacterial Potential of Streptomyces sp
Translational Biomedicine, 2015
Background and Objectives: Marine bacteria are recognized as an untapped resource of bioactive metabolites of diverse structure and functions. The present research is focused on the screening of the antagonistic potential of bacteria isolated from marine sponge against human and shrimp pathogens. Methods and Findings: In this study, a total of 51 strains of bacteria isolated from five species of marine sponges sourced from the Vizhinjam littoral (Indian Ocean) were screened for possible antagonistic activity against human and shrimp pathogens. Of the 51 bacterial isolates, twelve strains isolated from marine sponges, S.officinalis and D. nigra showed different ranges of activity. The results of agar-well diffusion assay showed that, out of the twelve strains, MAPS 15 strain showed the highest activity which subdued the growth of all the tested 20 bacterial pathogens. The molecular characterization based on partial 16S rRNA sequence revealed that the active isolate MAPS 15 was Streptomyces sp. Conclusion: This study serves as a basis for further research on the possibility of utilizing Streptomyces sp. for the development of human and veterinary grade antibiotics.
Microorganisms
Current treatment of chronic diseases includes, among others, application of cytokines, monoclonal antibodies, cellular therapies, and immunostimulants. As all the underlying mechanisms of a particular diseases are not always fully clarified, treatment can be inefficient and associated with various, sometimes serious, side effects. Small secondary metabolites produced by various microbes represent an attractive alternative as future anti-inflammatory drug leads. Compared to current drugs, they are cheaper, can often be administered orally, but still can keep a high target-specificity. Some compounds produced by actinomycetes or fungi have already been used as immunomodulators—tacrolimus, sirolimus, and cyclosporine. This work documents strong anti-inflammatory features of another secondary metabolite of streptomycetes—manumycin-type polyketides. We compared the effect of four related compounds: manumycin A, manumycin B, asukamycin, and colabomycin E on activation and survival of hum...
International Journal of Pharmacy and Pharmaceutical Sciences, 2015
Objective: To investigate the antimicrobial and cytotoxic activities of bioactive compounds produced by Streptomyces sp. KB1 isolated from the air sample at Ao-nang, Krabi province, Thailand. Methods: Streptomyces sp. KB1 was identified by 16S rDNA gene sequencing. It was preliminarily investigated the antibacterial activity by cross streak method and then cultivated in the half-formula of Luria Bertani at 30 °C, 200 rpm in shaking incubator for 7 d. Culture broth of each day was prepared as cell-free culture broth and tested the anti-Staphylococcus aureus TISTR 517 activity by agar well diffusion method along with determined the protein concentration by Bradford assay. Bioactive compounds were assessed the antimicrobial activity and cytotoxicity against brine shrimp by broth microdilution method and brine shrimp lethality bioassay, respectively. Results: Bioactive compounds were excreted into liquid culture medium within 2 d of cultivation and showed a broad spectrum of antibacterial activity. Whereas, the highest activity has shown since day 4 th of an incubation period which had protein concentration equal 254 ± 3.1 µg/ml. Bioactive compounds showed strong activity against Gram-positive bacteria, moderate activity against Gram-negative bacteria and weak activity against yeasts and Pseudomonas aeruginosa TISTR 1467. The MIC, MBC or MFC, and LC50 Conclusion: This study implied that bioactive compounds produced by Streptomyces sp. KB1 may be the important polypeptide compound that can be used as lead compounds for novel drug discovery. value of bioactive compounds were in the range of 0.49-63.50, 0.49-127.00, and 131.58 µg/ml, respectively.
The Antibacterial Activities of Secondary Metabolites Derived from Streptomyces sp
Progress in Microbes and Molecular Biology, 2022
The spreading of infectious diseases caused by the emergence of Multidrug-Resistant (MDR) pathogens is a global threat that has led to numerous deaths annually. In view of this, there is an overwhelming need to discover new bioactive compounds with effective antimicrobial properties. Concurrently, the genus Streptomyces has a growing reputation as a potential biological source of various antibiotics and other bioactive metabolites. Streptomyces sp. has been isolated from different sources, including terrestrial and marine habitats with a myriad of promising compounds that could be used to treat MDR pathogens. Therefore, this study presents a systematic review of the antibacterial activities of Streptomyces-derived secondary metabolites. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and checklist were employed in this study to collect relevant articles from two research databases, namely PubMed and Science Direct. The selection process includes identification, screening, eligibility, and inclusion of articles. Several keywords and criteria were established for the screening and selection process. Based on the results, a total of 26 articles were selected from 70 potential articles. The articles were published between 2015 and 2020 with most studies being published in 2020, indicating an increased interest in Streptomyces and its derived compounds. Approximately 51 different Streptomyces-derived compounds have been identified, ranging from crude extracts, pure PMMB 2022, 5, 1; a0000281 2 of 25 compounds, and partially purified compounds. Various parameters were also used to assess their antibacterial activities, particularly the Minimum Inhibitory Concentration (MIC) (69%) and the zone of inhibition (11%). Moreover, the antibacterial activities of these compounds were effective on numerous gram-positive and gram-negative bacteria. Furthermore, 46% and 54% of the selected studies were focused on inhibiting MDR and non-MDR pathogens, respectively. In conclusion, both crude and purified compounds from Streptomyces sp. exhibited strong antibacterial effects. It is expected that extensive future research would develop a standard method to compare the antibacterial strength of each extracted compound from Streptomyces sp. and determine the most effective bioactive compounds to treat diseases caused by MDR pathogens.
Veterinary Research Communications, 2011
Background: Streptococcus suis (SS) is a major swine pathogen and a serious zoonotic pathogen causing septicemia and meningitis in piglets and humans. Using an immunoproteomic approach, we previously brought evidence that ornithine carbamoytransferase (OCT) may represent a vaccine candidate to protect against S. suis biofilm-related and acute infections. Method: In this study, the gene encoding OCT was cloned into the expression vector pET-28a and the recombinant protein was expressed in Escherichia coli BL21. The immunogenicity and protective efficacy of the SS OCT was further investigated in a mouse model. Results: The protein was found to be expressed in vivo and elicited high antibody titers following SS infections in mice. An animal challenge experiment with SS showed that 62.5% of mice immunized with the OCT protein were protected. Using an in vitro competitive adherence inhibition assay of adherence, evidence was obtained that OCT could significantly reduce the number of SS cells adhered to porcine kidney PK-15 cells. The bacterial levels recovered in mice of the OCT immunized group were significantly decreased in some organs, compared with the control group. Conclusion: In summary, our results suggest that the recombinant SS OCT protein, which is involved in bacterial adherence, may efficiently stimulate an immune response conferring
Biosynthesis Of Anti-Inflammatory Immunosuppressive Metabolite By Streptomyces Variabilis Asu319
2016
Most immunosuppressive agents were initially developed as antibiotics produced by the genus <em>Streptomyces</em>. This investigation was devoted to explore the bioactive metabolite of the <em>Streptomyces variabilis</em> ASU319 extract and testing the purified active compound of this extract as an immunosuppressive agent in rats blood. Elucidation of the chemical structure and optimization of the active compound were studied as well. Antimicrobial activity was conducted using agar-well diffusion and disc diffusion assays. The antimicrobial metabolite was extracted from the fermentation broth by ethyl acetate and purified by TLC and silica gel column chromatography. The pure active compound was then subjected to spectroscopic analyses: <sup>1</sup>H NMR, Elemental analysis, IR and Mass spectra. The active antimicrobial compound was tested as an immunosuppressive agent by injection in the rat blood and the complete blood count (CBC) was determined....
Arquivos do Instituto Biológico
ABSTRACT: The genus Streptomyces is associated with the ability to produce and excrete a variety of bioactive compounds, such as antibiotic, antifungal and antiviral. Biological active polyketide and peptide compounds with applications in medicine, agriculture and biochemical research are synthesized by PKS-I and NRPS genes. The evaluation of the presence of these genes associated with the biosynthesis of secondary metabolites in different phytopathogenic Streptomyces strains were performed using degenerated primers. The positive signal was observed in 58/63 Streptomyces strains for NRPS gene, 43/63 for PKS-I, and for PKS-II all the 63 strains showed positive signal of amplification. These strains also were tested with double layer agar-well technique against bacterial with clinical importance, and it was possible to observe the Streptomyces spp. strains were able to inhibit the growth of 14, 20, 13 and 3 isolates Gram-positive and Gram-negative bacteria, Staphylococcus aureus (ATCC...